L’Oréal Institut Pasteur: Beauty giant funds 5-year skin microbiome drive in $50 million push

Sarah Mills | GlobalBeat

L’Oréal will pay Institut Pasteur $50 million over five years to decode how skin microbes influence aging, acne, and inflammatory disorders.

The French cosmetics group said the partnership, sealed on Thursday in Paris, is its largest single investment in basic dermatology research.

Skin microbiome science has raced forward since 2013, when the US National Institutes of Health ended its human microbiome program. L’Oréal has published more than 50 papers on bacterial diversity but lacked access to Pasteur’s century-old pathogen vaults and CRISPR labs. The deal gives the beauty company first rights to license any discovery that can be formulated into creams, serums, or prescription gels.

L’Oréal’s chief research officer, Barbara Lavernos, told reporters the money will fund 30 PhD students and 10 post-docs housed inside Pasteur’s 25th arrondissement campus. “We want to move from correlation to causation,” she said. “If we can prove that a single strain prevents eczema flare-ups, we will isolate it and add it to topical products.”

Institut Pasteur president Stewart Cole said the partnership keeps his budget intact after France’s 2025 research freeze. “ private funding is no longer optional,” he said. The institute will retain patent joint-ownership and the right to publish in peer-reviewed journals within 12 months of filing a patent.

The first trials start in September. Researchers will swab 3,000 volunteers across age brackets and ethnicities, sequencing bacterial DNA from forehead, forearm, and lower back. Data will be uploaded to an open-access portal managed by both partners, though L’Oréal gains a 6-month head start for any cosmetic application.

Investor reaction was muted. L’Oréal shares closed up 0.4 percent at €432.10 in Paris trading, adding €1.1 billion in market value. Analysts at Bernstein called the spend “sensible insurance” against niche brands touting probiotic skincare. Smaller rivals such as Mother Dirt and Gallinée already sell live-bacteria mists; Estée Lauder launched a “microbiome-friendly” serum last year.

Thursday’s agreement extends a 15-year relationship. In 2010 the two groups identified that Staphylococcus epidermidis strains can reduce inflammation. That work underpinned La Roche-Posay’s Lipikar line, now worth €400 million in annual sales. The new pact triples the previous budget and shifts focus from moisture barriers to microbial metabolites that may alter collagen breakdown.

Regulators are watching. The European Commission plans to add “microbiome-friendly” to its 2027 green labeling standards. Any product claiming bacterial balance will need third-party verification, a hurdle L’Oréal hopes to clear with Pasteur-backed data. “We want the science so solid that Brussels can’t say no,” Lavernos said.

Critics warn of corporate control over academic inquiry. Anne-Charlotte Vuccino, president of French advocacy group Sciences Citoyennes, said the contract should be published in full. “When public institutes accept exclusive licensing, citizens pay twice: first through taxes, then at the beauty counter,” she argued. Pasteur representatives counter that all results will be peer-reviewed and that licenses will be non-exclusive for medical uses.

Dermatologists greeted the news cautiously. Dr. Aline Donovan, a Paris-based clinician who sits on L’Oréal’s external advisory board, said the industry is “awash with marketing hype” around probiotics. “What we need are double-blind studies showing that adding a live strain outperforms conventional steroids,” she told GlobalBeat. The Pasteur program will run placebo-controlled trials for atopic dermatitis starting in 2027.

Background

The human skin harbors roughly 1 billion bacteria per square centimeter, forming a living shield that fends off pathogens and calms immune reactions. Scientists sequenced these communities only after 2008, when DNA costs collapsed. Early work linked low bacterial diversity to eczema and acne, but cause-and-effect remained elusive. Institut Pasteur’s genomics unit owns 12,000 bacterial isolates collected since 1904, giving L’Oréal a library unmatched in the cosmetics sector.

L’Oréal’s R&D budget hit €1.3 billion in 2025, yet only 8 percent targeted microbiome projects. The company has filed 125 bacterial patents since 2015, trailing Nestlé Skin Health’s 140. Thursday’s deal vaults it ahead in France, where strict lab rules limit foreign access to human samples. Pasteur scientists will share skin-biopsy collections from volunteers in Senegal, South Korea, and Mexico, adding geographic diversity missing from prior L’Oréal studies.

What’s Next

Regulators at the European Medicines Agency will meet in November to decide whether live-bacteria skincare qualifies as a drug or cosmetic. If recategorized, products would require Phase III trials costing up to €80 million per strain. L’Oréal said it will submit the first dossier by mid-2027, betting that Pasteur-generated safety data will ease approval. The firm aims to launch a prescription “bacterial gel” for adult acne before 2030.